Wexford Capital’s AYTU BioPharma AYTU Stock Holding History

Wexford Capital’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-509	Closed	-$123K	–	119
2019 Q3	$123K	Sell	509 -3,030	-86%	-$912K	0.02%	108
2019 Q2	$1.34M	Buy	3,539 +3,091	+690%	+$1.18M	0.16%	77
2019 Q1	$149K	Hold	448	–	–	0.01%	89
2018 Q4	$71K	Buy	+448	New	+$98.7K	0.01%	75

Other funds holding AYTU

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Searle & Co Greenwich, Connecticut $445M AUM 41.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wexford Capital's AYTU Position: Q4 2019 in Review

Wexford Capital sold out of AYTU BioPharma (AYTU) in Q4 2019, closing a stake of 509 shares — an estimated $123K sold.

Wexford Capital first reported a position in AYTU in Q4 2018 and held it in 4 quarters. The position peaked at $1.34M in Q2 2019. 8 funds tracked by Wall St. Rank hold AYTU as of Q4 2019.

Wexford Capital reported no remaining AYTU BioPharma position as of Q4 2019 after selling out during the quarter.
Wexford Capital sold 509 AYTU BioPharma shares in Q4 2019, an estimated $123K.
Wexford Capital first reported a position in AYTU BioPharma in Q4 2018 and held it in 4 quarters.
Wexford Capital's AYTU BioPharma position peaked at $1.34M in Q2 2019.
8 funds tracked by Wall St. Rank held AYTU BioPharma as of Q4 2019.

Based on Wexford Capital's 13F filing for Q4 2019, filed 14 Feb 2020.